Since the ground-breaking discovery of checkpoint blockade through anti-PD-1– and anti-PD-L1–based immunotherapy and the successful application of these immunotherapies in lung cancer, melanoma, etc., continuous efforts have focused on methods for identifying the patients most likely to respond to immunotherapy. This evidence concerns the gene CD274 and lung carcinoma.